was read the article
array:23 [ "pii" => "S2173574317300230" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.05.005" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "938" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2016" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2017;13:121-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 519 "formatos" => array:3 [ "EPUB" => 59 "HTML" => 267 "PDF" => 193 ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574317300229" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.05.004" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "932" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2017;13:122" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 807 "formatos" => array:3 [ "EPUB" => 61 "HTML" => 478 "PDF" => 268 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Similarities Between Takayasu Arteritis and Giant Cell Arteritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "122" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Similitudes entre la arteritis de Takayasu y la arteritis de células gigantes" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maria Noelia Antoniol, Carlos Edgardo Perandones" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Maria Noelia" "apellidos" => "Antoniol" ] 1 => array:2 [ "nombre" => "Carlos Edgardo" "apellidos" => "Perandones" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X16300481" "doi" => "10.1016/j.reuma.2016.05.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300481?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300229?idApp=UINPBA00004M" "url" => "/21735743/0000001300000002/v2_201703100919/S2173574317300229/v2_201703100919/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173574317300138" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.06.002" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "942" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2017;13:120-1" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 747 "formatos" => array:3 [ "EPUB" => 56 "HTML" => 532 "PDF" => 159 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Familial Mediterranean Fever Treated With Anakinra: A Case Report" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "120" "paginaFinal" => "121" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Fiebre mediterránea familiar en tratamiento con anakinra: a propósito de un caso" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Javier Espíldora-Hernández, Manuel Abarca-Costalago" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Javier" "apellidos" => "Espíldora-Hernández" ] 1 => array:2 [ "nombre" => "Manuel" "apellidos" => "Abarca-Costalago" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X16300596" "doi" => "10.1016/j.reuma.2016.06.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300596?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300138?idApp=UINPBA00004M" "url" => "/21735743/0000001300000002/v2_201703100919/S2173574317300138/v2_201703100919/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Response to: Uveitis due to Bisphosphonates: A Rare Side Effect?" "tieneTextoCompleto" => true "saludo" => "To the Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "121" "paginaFinal" => "122" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Walter Alberto Sifuentes-Giraldo, Cristina Clara Macía-Villa, Mónica Vázquez-Díaz" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Walter Alberto" "apellidos" => "Sifuentes-Giraldo" "email" => array:1 [ 0 => "albertosifuentesg@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Cristina Clara" "apellidos" => "Macía-Villa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Mónica" "apellidos" => "Vázquez-Díaz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Clínico Universitario de Valladolid, Valladolid, España" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta a: Uveítis por bifosfonatos: ¿un raro efecto secundario?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We read the letter published by Martín Guillén et al.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">1</span></a> very attentively. They presented a case of uveitis associated with treatment with bisphosphonates, and we would like to comment on our experience with this adverse effect, which we help might contribute to the proper identification of these cases.</p><p id="par0015" class="elsevierStylePara elsevierViewall">We performed a retrospective observational study in which we included the cases of uveitis that developed <span class="elsevierStyleItalic">de novo</span> during treatment with bisphosphonates. The study was performed in the emergency department of Hospital Universitario Ramón y Cajal in Madrid, between January 2003 and December 2012. The variables analyzed included age, sex, indication for antiresorptive therapy, comorbidities, type of bisphosphonate, time between starting treatment and the onset of uveitis, clinical manifestation, associated ocular inflammatory signs and symptoms and outcome.</p><p id="par0025" class="elsevierStylePara elsevierViewall">There were 18 cases of uveitis associated with bisphosphonates, all in women, with a mean age at the time of diagnosis of 64.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>11.3 years (range: 38–82); 61% had taken alendronate and 39% had received risedronate. The indication for treatment was primary osteoporosis in 10 cases and secondary in 6. In 5 cases (27%), there was a history of autoimmune disease, but without episodes of ocular inflammation prior to taking the bisphosphonate; the diagnoses were inflammatory bowel disease with or without associated spondyloarthritis (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3), adult-onset Still's disease (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1) and primary biliary cirrhosis (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1). The time between starting treatment and the development of uveitis was 30.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>18 months (range: 8–63). All the patients had unilateral (89%) or bilateral (11%) acute anterior uveitis, and the most widespread clinical presentation was the association of pain and ocular inflammation (56%). In 2 (11%), there were other concomitant ocular inflammatory disorders (superficial punctate keratitis [SPK] and follicular conjunctivitis, respectively), and 10 patients (56%) developed complications (cataracts 22%, synechiae 16%, vitreous detachment 16% and macular edema 5%). Retrospectively, we learned that, prior to uveitis, 3 patients had had other episodes of ocular inflammation during bisphosphonate therapy, corresponding to scleritis, episcleritis and SPK/blepharitis, respectively. All of the aforementioned patients received treatment with topical corticosteroids and cycloplegic agents. Bisphosphonate therapy was discontinued because of the ocular event in only 1 case (6%) and for another cause in 2 (11%), and was maintained in the rest (83%). During the follow-up period, after the first episode of uveitis (74<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20.4 months), remission was achieved in 72% of the cases and recurrent disease in 28%; however, 44% developed other ocular inflammatory events, including conjunctivitis, SPK and blepharitis.</p><p id="par0035" class="elsevierStylePara elsevierViewall">In our series, most of the cases of uveitis associated with bisphosphonates occurred in women over the age of 60 years, with no previous history of autoimmunity or any other predisposing ocular disease. This profile coincides with that reported in the study of the cohort of Canadian veterans by Etminan et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">2</span></a> All of the patients had received oral aminobisphosphonates, generally for a long period of time, until the adverse effect developed. In the published cases, there is an ample range from the initiation of the drug until the onset of uveitis, which goes from less than 24<span class="elsevierStyleHsp" style=""></span>h to several months, and is shorter with intravenous administration and longer with oral medication.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">3,4</span></a> In our series, there was also a high frequency of other associated ocular inflammatory signs and symptoms. Bisphosphonates have been related to a wide variety of ocular disorders, mostly inflammatory, including conjunctivitis, scleritis, episcleritis, keratitis, orbital inflammatory disease and retrobulbar neuritis.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">3,5,6</span></a> Bisphosphonate therapy was discontinued in only 1 of our patients because of uveitis, whereas, it was maintained in the majority, and this may have contributed to the rates of recurrence and the development of other ocular inflammatory disorders and sequelae.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Although the development of uveitis during bisphosphonate therapy is an uncommon adverse event, it is important that clinicians who prescribe these agents recognize this association, and that patients be informed about its signs and symptoms for its early diagnosis and treatment.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0055" class="elsevierStylePara elsevierViewall">The authors declare they have no conflicts of interest concerning the publication of this article.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of Interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Sifuentes-Giraldo WA, Macía-Villa CC, Vázquez-Díaz M. Respuesta a: Uveítis por bifosfonatos: ¿un raro efecto secundario? Reumatol Clin. 2017;13:121–122.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib0035" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uveitis due to bisphosphonates: a rare side effect? [Article in English, Spanish]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Martín Guillén" 1 => "R. Hurtado García" 2 => "A. Álvarez Cienfuegos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.reuma.2015.04.006" "Revista" => array:5 [ "tituloSerie" => "Reumatol Clin" "fecha" => "2016" "volumen" => "12" "paginaInicial" => "119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26091954" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0040" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Etminan" 1 => "F. Forooghian" 2 => "D. Maberley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1503/cmaj.111752" "Revista" => array:6 [ "tituloSerie" => "CMAJ" "fecha" => "2012" "volumen" => "184" "paginaInicial" => "E431" "paginaFinal" => "E434" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22470169" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0045" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Pazianas" 1 => "E.M. Clark" 2 => "P.A. Eiken" 3 => "K. Brixen" 4 => "B. Abrahamsen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jbmr.1783" "Revista" => array:6 [ "tituloSerie" => "J Bone Miner Res" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "455" "paginaFinal" => "463" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23044864" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0050" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.V. Patel" 1 => "M. Bolland" 2 => "Z. Nisa" 3 => "F. Al-Abuwsi" 4 => "M. Singh" 5 => "A. Horne" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00198-014-2872-5" "Revista" => array:6 [ "tituloSerie" => "Osteoporos Int" "fecha" => "2015" "volumen" => "26" "paginaInicial" => "499" "paginaFinal" => "503" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25187119" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0055" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced uveitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Cordero-Coma" 1 => "R. Salazar-Méndez" 2 => "I. Garzo-García" 3 => "T. Yilmaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14740338.2015.972363" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drug Saf" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "111" "paginaFinal" => "126" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25323655" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0060" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bisphosphonate-induced orbital inflammation: a case series and review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Pirbhai" 1 => "S.N. Rajak" 2 => "L.A. Goold" 3 => "T.S. Cunneen" 4 => "G. Wilcsek" 5 => "P. Martin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/01676830.2015.1078380" "Revista" => array:6 [ "tituloSerie" => "Orbit" "fecha" => "2015" "volumen" => "34" "paginaInicial" => "331" "paginaFinal" => "335" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26540241" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001300000002/v2_201703100919/S2173574317300230/v2_201703100919/en/main.assets" "Apartado" => array:4 [ "identificador" => "8400" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001300000002/v2_201703100919/S2173574317300230/v2_201703100919/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300230?idApp=UINPBA00004M" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 12 | 21 |
2024 October | 35 | 30 | 65 |
2024 September | 31 | 16 | 47 |
2024 August | 56 | 29 | 85 |
2024 July | 47 | 32 | 79 |
2024 June | 50 | 28 | 78 |
2024 May | 48 | 31 | 79 |
2024 April | 35 | 13 | 48 |
2024 March | 33 | 26 | 59 |
2024 February | 27 | 17 | 44 |
2024 January | 22 | 23 | 45 |
2023 December | 21 | 16 | 37 |
2023 November | 25 | 36 | 61 |
2023 October | 35 | 26 | 61 |
2023 September | 38 | 31 | 69 |
2023 August | 26 | 14 | 40 |
2023 July | 25 | 27 | 52 |
2023 June | 27 | 14 | 41 |
2023 May | 37 | 23 | 60 |
2023 April | 22 | 7 | 29 |
2023 March | 43 | 24 | 67 |
2023 February | 23 | 30 | 53 |
2023 January | 29 | 11 | 40 |
2022 December | 39 | 28 | 67 |
2022 November | 29 | 31 | 60 |
2022 October | 42 | 25 | 67 |
2022 September | 30 | 32 | 62 |
2022 August | 29 | 34 | 63 |
2022 July | 31 | 38 | 69 |
2022 June | 25 | 33 | 58 |
2022 May | 31 | 45 | 76 |
2022 April | 30 | 45 | 75 |
2022 March | 33 | 50 | 83 |
2022 February | 38 | 37 | 75 |
2022 January | 42 | 38 | 80 |
2021 December | 39 | 38 | 77 |
2021 November | 56 | 44 | 100 |
2021 October | 53 | 48 | 101 |
2021 September | 44 | 41 | 85 |
2021 August | 22 | 33 | 55 |
2021 July | 31 | 44 | 75 |
2021 June | 19 | 25 | 44 |
2021 May | 53 | 59 | 112 |
2021 April | 158 | 111 | 269 |
2021 March | 70 | 32 | 102 |
2021 February | 54 | 18 | 72 |
2021 January | 39 | 28 | 67 |
2020 December | 35 | 22 | 57 |
2020 November | 22 | 11 | 33 |
2020 October | 22 | 14 | 36 |
2020 September | 41 | 22 | 63 |
2020 August | 27 | 20 | 47 |
2020 July | 14 | 15 | 29 |
2020 June | 26 | 18 | 44 |
2020 May | 17 | 10 | 27 |
2020 April | 15 | 14 | 29 |
2020 March | 19 | 6 | 25 |
2020 February | 1 | 0 | 1 |
2019 September | 1 | 0 | 1 |
2018 December | 2 | 0 | 2 |
2018 May | 3 | 0 | 3 |
2018 April | 25 | 5 | 30 |
2018 March | 33 | 5 | 38 |
2018 February | 15 | 5 | 20 |
2018 January | 11 | 10 | 21 |
2017 December | 11 | 5 | 16 |
2017 November | 12 | 8 | 20 |
2017 October | 16 | 8 | 24 |
2017 September | 10 | 12 | 22 |
2017 August | 7 | 7 | 14 |
2017 July | 16 | 23 | 39 |
2017 June | 19 | 11 | 30 |
2017 May | 28 | 27 | 55 |
2017 April | 32 | 29 | 61 |
2017 March | 26 | 35 | 61 |
2017 February | 0 | 3 | 3 |